The Institute for Clinical and Economic Review (ICER) determined the price set by Geron for Rytelo (imetelstat) for the treatment of anemia in patients with low-to-intermediate risk myelodysplastic syndrome (MDS) “is far out of line with the modest short term benefit suggested by the clinical trials.”
Source: Drug Industry Daily